Cargando…

Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance

Background: Although human immunodeficiency virus type 1 (HIV-1) reservoir size is very stable under antiretroviral therapy (ART), individuals exposed to the Hepatitis C virus (HCV) (chronically coinfected and spontaneous clarifiers) show an increase in HIV reservoir size and in spliced viral RNA, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez-Román, Paula, Crespo-Bermejo, Celia, Valle-Millares, Daniel, Lara-Aguilar, Violeta, Arca-Lafuente, Sonia, Martín-Carbonero, Luz, Ryan, Pablo, de los Santos, Ignacio, López-Huertas, María Rosa, Palladino, Claudia, Muñoz-Muñoz, María, Fernández-Rodríguez, Amanda, Coiras, Mayte, Briz, Verónica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267476/ https://www.ncbi.nlm.nih.gov/pubmed/35806864 http://dx.doi.org/10.3390/jcm11133579

Ejemplares similares

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients
por: Martínez-Román, Paula, et al.
Publicado: (2020)

HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study
por: López-Huertas, Maria Rosa, et al.
Publicado: (2019)

903 Protein Saver cards: the best alternative for dried blood spot storage at room temperature for HCV RNA
por: Arca-Lafuente, Sonia, et al.
Publicado: (2022)

Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients
por: Valle-Millares, Daniel, et al.
Publicado: (2021)

Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status
por: Crespo-Bermejo, Celia, et al.
Publicado: (2021)

Molecular mechanisms involved in HIV latency and implications for HIV treatment and eradication
por: Alcami, Jose, et al.
Publicado: (2010)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

MicroRNA signature from extracellular vesicles of HCV/HIV co-infected individuals differs from HCV mono-infected
por: Cairoli, Victoria, et al.
Publicado: (2023)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
por: Maughan, A., et al.
Publicado: (2019)

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
por: Sacks‐Davis, Rachel, et al.
Publicado: (2018)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
por: Márquez-Coello, Mercedes, et al.
Publicado: (2021)

DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b
por: De Francesco, Maria Antonia, et al.
Publicado: (2022)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
por: Marino, Andrea, et al.
Publicado: (2021)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
por: Farcomeni, Stefania, et al.
Publicado: (2021)

Basal shuttle of NF-κB/IκBα in resting T lymphocytes regulates HIV-1 LTR dependent expression
por: Coiras, Mayte, et al.
Publicado: (2007)

Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits IκBα and enhances HIV-1 replication in human T lymphocytes
por: Coiras, Mayte, et al.
Publicado: (2008)

Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance
por: Franzè, Maria Stella, et al.
Publicado: (2022)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients
por: Salmon, Dominique, et al.
Publicado: (2018)

Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection
por: Chuaypen, Natthaya, et al.
Publicado: (2023)

Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance—Supercontrollers
por: Dominguez-Molina, Beatriz, et al.
Publicado: (2018)

IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle
por: Coiras, Mayte, et al.
Publicado: (2016)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

Identification of the transcripts associated with spontaneous HCV clearance in individuals co-infected with HIV and HCV
por: Chen, Yue, et al.
Publicado: (2016)

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
por: Brothers, Sarah, et al.
Publicado: (2022)

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
por: Ménard, A, et al.
Publicado: (2014)

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort
por: d'Arminio Monforte, Antonella, et al.
Publicado: (2017)

Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance
por: Duan, Siqin, et al.
Publicado: (2022)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Treatment of hepatitis C in HIV patients in the new DAA era
por: Soriano, Vicente
Publicado: (2014)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfected patients
por: Martínez-González, Elena, et al.
Publicado: (2020)

Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells
por: Sánchez-Del Cojo, María, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qqmjg664b090ngkjs9eg932at5